2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Abstract Number: 156

Teaching High Value Musculoskeletal Care Through Online Simulation Cases
Abstract Number: 36

The Association of Obesity with Pediatric Psoriatic Arthritis
Abstract Number: 69

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Abstract Number: 117

The Effect of Bisphosphonate Use on Bone Density Measurements in Patients with Muscular Dystrophy
Abstract Number: 19

The Lymphocyte Repertoire in Juvenile Dermatomyositis
Abstract Number: 86

The myositis-specific autoantibody and myositis-associated autoantibody phenotypes in Japanese juvenile idiopathic inflammatory myopathies
Abstract Number: 103

The Performance of a New Risk Assessment Scoring System in Detecting IVIG Resistance in Kawasaki Disease as Compared to the Kobayashi and Egami Scores in a Large Single Centre Canadian Cohort
Abstract Number: 51

The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Abstract Number: 34

The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 43

Tocilizumab Use in Pediatrics With Systemic Juvenile Idiopathic Arthritis: Single Center Data
Abstract Number: 153

Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum
Abstract Number: 54

Treatment and 1-year outcomes of an inception cohort of Australian children with JIA
Abstract Number: 80

Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades
Abstract Number: 128

Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells
Abstract Number: 50

Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients

Jump to: View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].